The Allstate Corporation (ALL)
NYSE: ALL · Real-Time Price · USD
199.77
-3.48 (-1.71%)
At close: Aug 1, 2025, 4:00 PM
191.16
-8.61 (-4.31%)
After-hours: Aug 1, 2025, 7:24 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $228.29, which forecasts a 14.28% increase in the stock price over the next year. The lowest target is $197 and the highest is $267.
Price Target: $228.29 (+14.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Buy | 6 | 6 | 7 | 8 | 7 | 7 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 15 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $235 → $245 | Buy | Maintains | $235 → $245 | +22.64% | Aug 1, 2025 |
| Barclays | Barclays | Sell Maintains $188 → $198 | Sell | Maintains | $188 → $198 | -0.89% | Jul 31, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Buy Maintains $235 → $237 | Buy | Maintains | $235 → $237 | +18.64% | Jul 9, 2025 |
| UBS | UBS | Strong Buy Maintains $230 → $235 | Strong Buy | Maintains | $230 → $235 | +17.64% | Jul 9, 2025 |
| Barclays | Barclays | Sell Maintains $172 → $188 | Sell | Maintains | $172 → $188 | -5.89% | Jul 7, 2025 |
Financial Forecast
Revenue This Year
60.52B
from 64.11B
Decreased by -5.59%
Revenue Next Year
65.52B
from 60.52B
Increased by 8.26%
EPS This Year
18.34
from 16.99
Increased by 7.94%
EPS Next Year
21.90
from 18.34
Increased by 19.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 64.5B | 70.2B | 75.2B | ||
| Avg | 60.5B | 65.5B | 70.7B | ||
| Low | 56.1B | 62.0B | 65.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.6% | 16.0% | 14.8% | ||
| Avg | -5.6% | 8.3% | 7.9% | ||
| Low | -12.5% | 2.4% | -0.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 21.32 | 27.14 | 27.39 |
| Avg | 18.34 | 21.90 | 23.39 |
| Low | 14.75 | 19.12 | 20.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 25.5% | 48.0% | 25.1% |
| Avg | 7.9% | 19.4% | 6.8% |
| Low | -13.2% | 4.2% | -8.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.